{
    "nct_id": "NCT05640193",
    "official_title": "Pilot Trial of Lifileucel (LN-144) for Patients With Asymptomatic Melanoma Brain Metastases and Progression on Prior PD1 Therapy",
    "inclusion_criteria": "1. Metastatic melanoma with asymptomatic brain metastases\n2. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL\n3. Must be ≥ 18 years of age at time of consent\n4. ECOG performance status of 0-1 and estimated life expectancy of ≥ 3 months\n5. Adequate hematologic parameters and organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Received organ allograft, except kidney transplant, or prior cell transfer therapy including TIL and CAR-T therapies\n2. Ongoing grade 2-4 toxicity from prior immunotherapy (excluding endocrine, ocular toxicity or vitiligo)\n3. History of hypersensitivity to any component or excipient of lifileucel or other treatment regimen drugs\n4. Symptomatic brain metastases\n5. Chronic systemic steroid therapy of > 10 mg/day\n6. Active medical illness(es) that would pose increased risk for protocol participation\n7. Must have negative syphilis assay and be seronegative for HIV, positive serology for HBV must have corresponding PCR assay and may be enrolled if viral load by PCR is undetectable\n8. Primary immunodeficiency\n9. Received live or attenuated vaccine within 28 days prior to beginning NMA-LD\n10. Pregnant or breastfeeding\n11. Patients who cannot receive gadolinium-enhanced MRI.",
    "miscellaneous_criteria": ""
}